How we do it

Everyone at GSK focuses on three priorities: Innovation, Performance, Trust

Innovation

We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients, payers and consumers.

£3.9bn

Research and Development investment in 2018

44

new medicines in development at Q2 2019

17

oncology assets in our pipeline at Q2 2019, which has more than doubled from 8 in the last 12 months

 

 

Performance

We aim to achieve industry-leading growth by investing effectively in our business, developing our people and delivering flawlessly.

£30.8bn

total turnover in 2018

£8.7bn

adjusted operating profit in 2018

£5.7bn

free cash flow in 2018

£3.9bn

dividends paid in 2018

 

Trust

We are a responsible company and commit to use our science and technology to address health needs, make our products affordable and available and to be a modern employer. 

78%

employee engagement score on our latest employee survey

£224m

donated in 2018 to community health programmes

1st

in Access to Medicines Index since the assessment began in 2008